This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.

开始日期2022-11-30

申办/合作机构

National Cancer Institute

NCT05151328

/ Completed临床3期

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Plecanatide in the Treatment of Functional Constipation in Chinese Patients for up to 12 Weeks

This is a multi-center, randomized, double-blind, Placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Plecanatide in the treatment of Functional Constipation in Chinese patients for up to 12 weeks.
Patients will enter a Screening period which must undergo a 2-week Pre-Treatment assessment, they will complete daily assessments of electronic dairy to demonstrate the eligibility.
Eligible subjects will be randomized into Plecanatide 3 mg group or Placebo group at Visit 1 at the ratio of 1:1 and take an oral dose of study treatment continuously for 12 weeks. For 2 weeks after complete dosing patients will continue to complete daily electronic dairy. Patients will then return to the clinical site for efficacy and safety assessment as part of an End of Study visit. The planned duration of participation in this study will be 154 days and up to 164 days with all windows considered.

开始日期2022-03-18

申办/合作机构

山东罗欣药业集团股份有限公司

CTRI/2022/03/040704

/ Completed临床3期

A Randomized, Double-Blind, Multicentric, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Plecanatide in Subjects with Chronic Idiopathic Constipation or Irritable Bowel Syndrome with Constipation.

开始日期2022-03-05

申办/合作机构

MSN Laboratories Pvt Ltd.

100 项与普卡那肽相关的临床结果

登录后查看更多信息

100 项与普卡那肽相关的转化医学

登录后查看更多信息

100 项与普卡那肽相关的专利（医药）

登录后查看更多信息

111

项与普卡那肽相关的文献（医药）

2024-12-01·Gastroenterology & hepatology

Efficacy and Safety of Plecanatide in Treatment of Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation.

Article

2024-12-01·Gastroenterology & hepatology

Plecanatide Is Efficacious in Patients With Irritable Bowel Syndrome With Constipation and Bloating: Evaluation Using Trisymptom Composite Endpoints.

Article

2024-10-01·Journal of Managed Care & Specialty Pharmacy

A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States

Article

作者: Cash, Brooks D. ; Feuerstadt, Paul ; Moshiree, Baharak ; Terasawa, Emi ; Pi, Selina ; Lembo, Anthony ; Lu, Mei ; Ayyagari, Rajeev ; Boules, Mena ; Du, Shawn ; Westermeyer, Ben ; Nguyen, Linda ; Terreri, Brian

BACKGROUND:

At present, 4 prescription therapies have been approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation (CIC) in adults.

OBJECTIVES:

To compare persistence with and adherence to prucalopride vs 3 other prescription medications for CIC in a US population.

METHODS:

This retrospective, observational cohort study used data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (January 2015-June 2020). Inclusion criteria were patients (aged ≥18 years) with at least 1 prescription fill for prucalopride, lubiprostone, linaclotide, or plecanatide on or after April 2, 2019 (commercial availability of prucalopride), and at least 1 constipation-related diagnosis code. Persistence was assessed by time to discontinuation, and adherence was assessed by the proportion of days covered (PDC) and the proportion of patients who achieved PDC of at least 80%. Adjusted hazard ratios (HRs) for discontinuation and odds ratios for adherence were calculated.

RESULTS:

A total of 14,700 patients (mean age = 48.3 years; female = 81.9%) were included (prucalopride, n = 675; lubiprostone, n = 1,591; linaclotide, n = 11,105; plecanatide, n = 1,329). After adjusting for confounding factors, the HRs for discontinuation were significantly higher for all comparator medications compared with prucalopride after 2 months (HR [95% CI]: lubiprostone, 1.70 [1.48-1.95]; linaclotide, 1.25 [1.10-1.41]; plecanatide, 1.31 [1.13-1.51], all P < 0.001). The unadjusted mean (SD) PDC was 0.53 (0.32) with prucalopride compared with 0.41 (0.31); P less than 0.001 with lubiprostone, 0.48 (0.31), P less than 0.05 with linaclotide, and 0.48 (0.29), P = 0.98 with plecanatide. The comparator medications were all associated with lower odds of achieving PDC of at least 80% relative to prucalopride (odds ratio [95% CI]: lubiprostone, 0.52 [0.40-0.69], P < 0.001; linaclotide, 0.73 [0.58-0.93], P = 0.009; plecanatide, 0.70 [0.53-0.93], P = 0.015).

CONCLUSIONS:

The findings of this study indicate that prucalopride has higher treatment persistence and adherence compared with other CIC prescription medications. This research represents the first instance of a real-world claims study showcasing such outcomes.

项与普卡那肽相关的新闻（医药）

2025-03-12

·E药经理人

百亿抑酸蓝海再掀热潮，罗欣药业P-CAB注射剂研发又有新进展‌！

在医药行业监管趋严、同质化竞争加剧的背景下，创新性临床试验已成为企业重构竞争壁垒的核心引擎。近日，罗欣药业（股票代码：002793.SZ）发布公告，其下属子公司山东罗欣药业集团股份有限公司、罗欣药业（上海）有限公司已正式获得国家药品监督管理局下发的《药物临床试验批准通知书》，注射用LX22001新增适应症“预防重症患者应激性溃疡出血”获批开展临床试验。图为：国家药品监督管理局药品审评中心公示 01 有望成为全球首个P-CAB注射剂型注射用LX22001是钾离子竞争性酸阻滞剂类药物（P-CAB），其抑制酸分泌的作用机制为竞争性结合壁细胞内H+/K+-ATP酶（质子泵）的钾离子结合部位。与质子泵抑制剂（PPI）不同，P-CAB可直接抑制H+/K+-ATP酶，而无需在强酸环境下活化。而且，无论H+/K+-ATP酶活化与否，P-CAB均可与之结合[1]。据罗欣药业公开资料介绍，注射用LX22001于2024年6月首次获批开展临床试验，适应症为：（1）当口服疗法不适用时，用于反流性食管炎、十二指肠溃疡的替代疗法；（2）消化性溃疡出血。本次获批临床试验的新适应症为“预防重症患者应激性溃疡出血”。应激性溃疡（SU）是机体在各类严重创伤、危重疾病或严重心理疾病等应激状态下发生的急性胃肠道黏膜糜烂、溃疡等病变，严重者可并发消化道出血甚至穿孔，可使原有疾病的程度加重及恶化，增加病死率[2]。临床数据显示，在ICU危重症患者中，约有5%~25%的患者会出现不同程度的ICU急性消化道出血，而应激性溃疡则是其中的主要诱因之一[3]。SU出血一旦发生，可使病死率显著升高，高达50%~80%，是ICU危重症患者最常见的死亡原因之一[4]。以往，针对应激性溃疡，临床主要依赖于常见的抑酸药物[2]，但药效和针对性并不能满足所有患者的需求，亟需有效的药物、医疗措施来加以预防，减少患者痛苦。此次“预防重症患者应激性溃疡出血”新增适应症获批开展临床试验，无疑为广大重症患者带来了福音，也标志着这一新剂型将进一步拓展临床应用范围，特别是对于手术、住院等无法口服治疗的患者群体，将进一步满足抑酸治疗的临床需求。 2023年中国抑酸市场Value IQVIA数据显示，中国抑酸市场体量巨大，整体抑酸剂市场规模可达200亿元以上，其中注射剂以55%份额主导市场。注射用LX22001全球范围内尚无同类注射剂产品上市，有望填补市场空白，为罗欣药业业绩大添增量。罗欣药业此次布局P-CAB注射剂型，也将进一步丰富公司消化管线，形成口服与注射剂型的协同效应，通过差异化优势进一步巩固在消化领域的市场地位，并抢占未来抑酸药物迭代升级的先机。 02 国家1类创新药泰欣赞®或已全面进入收获期 2022年4月，罗欣药业消化疾病领域重磅产品、国家1类创新药泰欣赞®获批上市，用于治疗反流性食管炎（RE）；2023年11月，新适应症十二指肠溃疡（DU）获批上市；2024年10月，新适应症“与适当的抗生素联用以根除幽门螺杆菌（Hp）”获批上市。泰欣赞®是中国首款自研、首个获批三项适应症(Hp/RE/DU)的钾离子竞争性酸阻滞剂（P-CAB），也是山东省首个国家1类化学创新药，具有30分钟快速起效、强效持久抑酸、服用方便等特点，RE/DU两项适应症被纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》，为临床用药带来新选择。据悉，为做好泰欣赞®商业化，罗欣药业自建创新直营模式，组建了一支400余人，由直营销售部、市场投资部、医学部、商务部及运营分析部等部门构成的完整创新药商业化团队。通过消化领域核心创新产品泰欣赞®的商业化实践，积累了大量的临床、商业化经验，使罗欣药业在创新药产品商业化方面具有准入更快速、商业化成功率更高的优势，为后续获批上市的创新药产品快速、成功商业化，并降低综合运营成本奠定基础，从而进一步巩固并提升罗欣药业在创新药领域的综合竞争实力。记者从罗欣药业了解到，泰欣赞®自2022年上市后快速实现商业化覆盖，至今已准入全国2000余家医院，包括北京协和医院、解放军总医院、华西医院等头部医疗机构。同时，为了满足抑酸患者的购买便利需求，罗欣药业已在浙江地区率先试点零售药店销售，未来将逐步拓展至全国连锁渠道，进一步扩大市场增量。 03 罗欣药业创新之路，再迈坚实步伐近年来，罗欣药业坚持科技创新，坚持“自主研发+合作研发”双轨并进，逐步打造了以消化、呼吸系统疾病和儿童用药为主线、兼顾抗肿瘤等多个治疗领域的创新产品研发管线，继续强化在消化和呼吸领域所具备的显著竞争优势，促进创新科研成果不断落地。除泰欣赞®外，普卡那肽现已完成III期临床研究，达成主要疗效终点，有望成为国内首个治疗慢性特发性便秘的鸟苷酸环化酶激动剂。FMT肠道菌群移植领域，与国际领先的AI+BT微生态研发企业-深圳未知君达成战略合作，并签署《独家代理经销合作协议》。该技术可用于治疗多种菌群失调相关性疾病，应用安全，范围广泛，潜力巨大。2024年国家已设立该领域的重大专项，罗欣药业与深圳未知君正在积极推进全国FMT医院终端准入工作和科研合作，近期大型三甲医院将陆续开展招标工作，罗欣药业销售团队已完成投标策略部署，积极推动该技术规范化应用场景落地。本次注射用LX22001新增适应症获批临床试验，标志着罗欣药业科技创新工作又迈出了坚实的一步，体现了罗欣药业在保持该领域的技术优势的基础上持续发力，彰显了企业科技创新能力，有助于丰富产品管线，提升公司核心竞争力。未来，罗欣药业将持续秉持“传递健康”理念，深耕消化领域，进一步做强、做大优势产品，重点挖掘并解决上下消化道及消化腺肝胆胰相关疾病治疗中未被满足的、迫切的临床需求，持续推进高质量创新药品研发成果落地，为全球患者提供更多创新药物选择。参考文献: [1]杨君,刘芳,臧雷.新型钾离子竞争性酸阻滞剂:替戈拉生[J].中国新药与临床杂志, 2022(041-005).DOI:10.14109/j.cnki.xyylc.2022.05.04. [2] 柏愚, 李延青, 任旭, 等. 应激性溃疡防治专家建议(2018版) [J] . 中华医学杂志, 2018, 98(42) : 3392-3395. [3]Tauseef, Ali,Richard F, Harty,Stress-induced ulcer bleeding in critically ill patients.[J] .Gastroenterol Clin North Am, 2009, 38: 0. [4]Zhou, Xiaoyang et al. “Stress ulcer prophylaxis with proton pump inhibitors or histamine 2 receptor antagonists in critically ill adults - a meta-analysis of randomized controlled trials with trial sequential analysis.” BMC gastroenterology vol. 19,1 193. 21 Nov. 2019, doi:10.1186/s12876-019-1105-y 一审| 黄佳二审| 李芳晨三审| 李静芝

申请上市核酸药物

2025-03-11

·罗欣药业

罗欣药业注射用LX22001新增适应症获批开展临床试验

近日，罗欣药业集团股份有限公司（股票代码：002793.SZ，以下简称“罗欣药业”）下属子公司山东罗欣药业集团股份有限公司、罗欣药业（上海）有限公司已正式获得国家药品监督管理局下发的《药物临床试验批准通知书》，注射用LX22001新增适应症“预防重症患者应激性溃疡出血”获批开展临床试验。图为：国家药品监督管理局药品审评中心公示有望成为全球首个P-CAB注射剂型注射用LX22001是钾离子竞争性酸阻滞剂类药物（P-CAB），目前在全球范围内尚无同类注射剂产品上市。其抑制酸分泌的作用机制为竞争性结合壁细胞内H+/K+-ATP酶（质子泵）的钾离子结合部位。与质子泵抑制剂（PPI）不同，P-CAB可直接抑制H+/K+-ATP酶，而无需在强酸环境下活化。而且，无论H+/K+-ATP酶活化与否，P-CAB均可与之结合[1]。 2024年6月，罗欣药业研发的注射用LX22001首次获批开展临床试验，适应症为：（1）本品可作为当口服疗法不适用时，用于下列病症的替代疗法：反流性食管炎、十二指肠溃疡；（2）消化性溃疡出血。此次“预防重症患者应激性溃疡出血”新增适应症获批开展临床试验，标志着这一新剂型将进一步拓展其临床应用范围，特别针对手术、住院等无法口服治疗的患者群体，将进一步满足抑酸治疗的临床需求。中国抑酸市场体量巨大，整体抑酸剂市场规模可达200亿元以上，其中注射剂以55%份额主导市场。注射用LX22001全球范围内尚无同类注射剂产品上市，有望填补市场空白，为罗欣药业业绩大添增量。不仅如此，罗欣药业此次布局P-CAB注射剂型，将进一步丰富公司消化管线，形成口服与注射剂型的协同效应，通过差异化优势进一步巩固在消化领域的市场地位，并抢占未来抑酸药物迭代升级的先机。国家1类创新药泰欣赞®已全面进入收获期 2022年4月，罗欣药业消化疾病领域重磅产品、国家1类创新药泰欣赞®获批上市，用于治疗反流性食管炎（RE）；2023年11月，新适应症十二指肠溃疡（DU）获批上市；2024年10月，新适应症“与适当的抗生素联用以根除幽门螺杆菌（Hp）”获批上市。泰欣赞®是中国首款自研、首个获批三项适应症(Hp/RE/DU)的钾离子竞争性酸阻滞剂（P-CAB），也是山东省首个国家1类化学创新药，具有30分钟快速起效、强效持久抑酸、服用方便等特点，RE/DU两项适应症被纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》，为临床用药带来新选择。为做好泰欣赞®商业化，罗欣药业自建创新直营模式，组建了一支400余人，由直营销售部、市场投资部、医学部、商务部及运营分析部等部门构成的完整的创新药商业化团队。通过消化领域核心创新产品泰欣赞®的商业化实践，积累了大量的临床、商业化经验，使罗欣药业在创新药产品商业化方面具有准入更快速、商业化成功率更高的优势，为后续获批上市的创新药产品快速、成功商业化，并降低综合运营成本奠定基础，从而进一步巩固并提升罗欣药业在创新药领域的综合竞争实力。泰欣赞®自2022年上市后快速实现商业化覆盖，至今已准入全国2000余家医院，包括北京协和医院、解放军总医院、华西医院等头部医疗机构；与此同时，为了满足抑酸患者的购买便利需求，罗欣药业已在浙江地区率先试点零售药店销售，未来将逐步拓展至全国连锁渠道，进一步扩大市场增量。罗欣药业创新之路，再迈坚实步伐罗欣药业坚持科技创新，坚持“自主研发+合作研发”双轨并进，逐步打造了以消化、呼吸系统疾病和儿童用药为主线、兼顾抗肿瘤等多个治疗领域的创新产品研发管线，继续强化在消化和呼吸领域所具备的显著竞争优势，促进创新科研成果不断落地。除泰欣赞®外，普卡那肽现已完成III期临床研究，达成主要疗效终点，有望成为国内首个治疗慢性特发性便秘的鸟苷酸环化酶激动剂。FMT肠道菌群移植领域，与国际领先的AI+BT微生态研发企业-深圳未知君达成战略合作，并签署《独家代理经销合作协议》。该技术可用于治疗多种菌群失调相关性疾病，应用安全，范围广泛，潜力巨大。2024年国家已设立该领域的重大专项，罗欣药业与深圳未知君正在积极推进全国FMT医院终端准入工作和科研合作，近期大型三甲医院将陆续开展招标工作，罗欣药业销售团队已完成投标策略部署，积极推动该技术规范化应用场景落地。本次注射用LX22001新增适应症获批临床试验，标志着罗欣药业科技创新工作又迈出了坚实的一步，体现了罗欣药业在保持该领域的技术优势的基础上持续发力，彰显了公司科技创新能力，有助于丰富产品管线，提升公司核心竞争力。未来，罗欣药业将持续秉持“传递健康”理念，深耕消化领域，进一步做强、做大优势产品，重点挖掘并解决上下消化道及消化腺肝胆胰相关疾病治疗中未被满足的、迫切的临床需求，持续推进高质量创新药品研发成果落地，为全球患者提供更多创新药物选择。参考文献 [1]杨君,刘芳,臧雷.新型钾离子竞争性酸阻滞剂:替戈拉生[J].中国新药与临床杂志, 2022(041-005).DOI:10.14109/j.cnki.xyylc.2022.05.04. 关于罗欣药业罗欣药业集团股份有限公司（简称“罗欣药业”，002793.SZ）始创于1988年，秉承“传递健康”的企业使命，以科技创新为己任，专注于消化、呼吸、抗肿瘤等疾病领域未满足的临床需求，致力于为患者提供更多创新药物选择。罗欣药业已上市丰富且有竞争力的产品组合，核心产品处于消化、呼吸疾病用药市场领先地位。公司多个产品被列入“国家重点新产品计划”、“国家火炬计划”、“重大新药创制”等科技重大专项。公司自2006年开始连续进入中国制药工业百强企业，自2011年以来连续被评为中国医药研发产品线最佳工业企业，是国家重点高新技术企业、国家技术创新示范企业、全国工业质量标杆企业，多项产品科研成果获得国家科学技术进步二等奖。更多信息，请访问www.luoxin.cn

上市批准申请上市临床申请

2024-08-01

·ir.bauschhealth.com

Bausch Health Announces Second Quarter 2024 Results

Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basis Consolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10% Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAVAL, QC, August 1, 2024 – Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter. "We continued our momentum in the second quarter, delivering our fifth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA, underscoring the strength of our product and geographic footprint and reinforcing our strategy. We remain focused on advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive growth globally. I'm proud of the hard work and accomplishments of our team, who work tirelessly to improve the health of patients worldwide," said Thomas J. Appio, Chief Executive Officer, Bausch Health. Second Quarter 2024 Revenue Performance Total consolidated reported revenues were $2.40 billion for the second quarter of 2024, compared with $2.17 billion in the second quarter of 2023, an increase of $236 million, or 11%. Excluding the impact of foreign exchange of $25 million, acquisitions of $104 million, and divestitures and discontinuations of $14 million, revenue increased by 8% organically1 compared with the second quarter of 2023. Reported revenues by segment were as follows: Three Months Ended June 30, Reported Change Change at Constant Currency1 (Non-GAAP) Change in Organic Revenue1 (Non-GAAP) (in millions) 2024 2023 Amount Pct. Total Bausch Health Revenues $2,403 $2,167 $236 11% 12% 8% Bausch Health (excl. B+L) $1,187 $1,132 $55 5% 5% 6% Salix segment $558 $557 $1 —% —% 1% International segment $276 $259 $17 7% 5% 6% Solta Medical segment $102 $88 $14 16% 19% 19% Diversified segment $251 $228 $23 10% 10% 12% Bausch + Lomb segment $1,216 $1,035 $181 17% 20% 10% Salix Segment Salix segment reported revenues were $558 million for the second quarter of 2024, compared with $557 million for the second quarter of 2023. Excluding the impact of divestitures and discontinuations of $5 million, segment revenues increased 1% on an organic1 basis. Xifaxan® revenues grew 10% compared with the second quarter of 2023, which was offset by declines in Relistor®, Trulance®, and certain non-promoted products. International Segment International segment reported revenues were $276 million for the second quarter of 2024, compared with $259 million for the second quarter of 2023, an increase of $17 million, or 7%. Excluding the impact of foreign exchange of $5 million and divestitures and discontinuations of $3 million, segment revenues increased organically1 by 6% compared with the second quarter of 2023, led by double-digit growth in Canada and solid growth in Latin America. Solta Medical Segment Solta Medical segment reported revenues were $102 million for the second quarter of 2024, compared with $88 million in the second quarter of 2023, an increase of $14 million, or 16%, which was driven by growth in Asia-Pacific, led by South Korea. Excluding the impact of foreign exchange of $3 million, segment revenues increased organically1 by 19% compared with the second quarter of 2023. Diversified Segment Diversified segment reported revenues were $251 million for the second quarter of 2024, compared with $228 million for the second quarter of 2023, an increase of $23 million, or 10%. Excluding the impact of divestitures and discontinuations of $4 million, segment revenues increased 12% on an organic1 basis, primarily attributable to increases in sales in Dermatology and Neurology. Bausch + Lomb Segment Bausch + Lomb segment reported revenues were $1,216 million for the second quarter of 2024, compared with $1,035 million for the second quarter of 2023, an increase of $181 million, or 17%. Excluding the impact of foreign exchange of $27 million, acquisitions of $104 million and divestitures and discontinuations of $2 million, the Bausch + Lomb segment revenues increased organically1 by 10% compared with the second quarter of 2023, driven by increases across all business units. 1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures and ratios to the most directly comparable GAAP measure. Read More View original release here: https://www.accesswire.com/viewarticle.aspx?id=894962

财报并购

100 项与普卡那肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09948	普卡那肽	A06AX07	DB13170

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肠易激综合征	加拿大	Bausch Health Cos., Inc.	2022-01-12
便秘型肠易激综合征	美国	Salix Pharmaceuticals, Inc.	2018-01-24
慢性特发性便秘	美国	Salix Pharmaceuticals, Inc.	2017-01-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
功能性便秘	临床3期	中国	山东罗欣药业集团股份有限公司	2022-03-03
功能性便秘	临床3期	中国	Salix Pharmaceuticals, Inc.	2022-03-03
便秘	临床3期	美国	Bausch Health Americas, Inc.	2014-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2020	N/A	便秘型肠易激综合征	-	Plecanatide 3 mg	願襯糧簾鑰鹹齋餘齋網(遞鬱醖蓋膚窪願襯觸遞) = 廠觸鏇壓醖淵遞窪襯築醖鑰願積鹽鑰餘廠衊觸 (願選艱襯鑰遞憲蓋製顧 ) 更多	-	2020-10-11
				Plecanatide 6 mg	願襯糧簾鑰鹹齋餘齋網(遞鬱醖蓋膚窪願襯觸遞) = 簾製鬱淵獵繭衊製製鑰醖鑰願積鹽鑰餘廠衊觸 (願選艱襯鑰遞憲蓋製顧 ) 更多
NCT02706483 (IBS-C, CTgov)	临床3期	便秘型肠易激综合征	2,272	Plecanatide	夢鹹蓋淵壓廠衊遞範糧 = 廠繭鑰衊積窪構鏇夢襯繭窪壓膚壓範鹽鹽築蓋 (艱簾憲製衊襯淵醖繭窪, 遞鬱衊鬱繭製選蓋鹽顧 ~ 齋廠廠齋積餘觸鏇築簾) 更多	-	2020-08-18
NCT01053962 (CIC, CTgov)	临床2期	慢性特发性便秘	84	SP-304 0.3 mg (SP-304 0.3 mg)	糧觸蓋範廠鬱膚齋遞憲 = 淵獵顧製壓簾膚選窪鑰遞選艱構製獵壓鹹願鹽 (獵簾簾繭鏇鏇糧夢膚鹽, 餘壓醖顧鑰壓糧醖鏇遞 ~ 網顧壓憲願壓鹽鑰願鹹) 更多	-	2020-01-02
				SP-304 1.0 mg (SP-304 1.0 mg)	糧觸蓋範廠鬱膚齋遞憲 = 淵遞蓋繭鹹範艱鏇餘鬱遞選艱構製獵壓鹹願鹽 (獵簾簾繭鏇鏇糧夢膚鹽, 築鑰顧醖鑰獵衊醖鬱憲 ~ 醖衊鹽構淵鑰觸鏇壓簾) 更多
NCT03120520 (CTgov)	临床2期	慢性特发性便秘	124	Matching placebo (Matching Placebo)	鏇衊獵製齋夢衊構餘鏇 = 餘鬱願築積鹹範選鏇夢鑰窪範醖獵鹹鏇簾衊鹽 (簾構構鹽構膚網製糧觸, 壓繭衊願餘繭醖鬱觸願 ~ 鹽齋醖顧齋構膚顧觸觸) 更多	-	2019-09-19
				Plecanatide (Plecanatide 0.5 mg)	鏇衊獵製齋夢衊構餘鏇 = 窪簾觸獵繭窪衊餘顧餘鑰窪範醖獵鹹鏇簾衊鹽 (簾構構鹽構膚網製糧觸, 網壓獵衊鑰構壓醖積餘 ~ 鹹遞膚築鏇範鬱積糧壓) 更多
NCT01919697 (CTgov)	临床3期	慢性特发性便秘	2,370	Plecanatide (Plecanatide 3 mg)	觸膚遞蓋膚鹽齋積齋選 = 網鹹糧鬱積顧鬱顧願齋鏇範廠窪範獵夢繭積餘 (範壓衊範鹹鏇選壓襯衊, 願願願齋膚鹽鹹餘選襯 ~ 夢窪選網鹽選獵選築觸) 更多	-	2019-07-02
				Plecantide (Plecantide 6 mg)	觸膚遞蓋膚鹽齋積齋選 = 餘觸糧襯築襯網繭製鏇鏇範廠窪範獵夢繭積餘 (範壓衊範鹹鏇選壓襯衊, 蓋憲襯鹹遞選獵齋鑰鬱 ~ 範醖夢齋觸築鬱壓膚膚) 更多
NCT02493452 (IBS-C, CTgov)	临床3期	便秘型肠易激综合征	1,135	Placebo (Matching Placebo)	築憲鬱選願餘積鑰鬱鹹 = 蓋廠淵選艱鏇衊遞鹽築觸獵壓糧齋繭選齋糧鑰 (醖簾構觸壓餘觸壓廠顧, 簾餘鹽膚艱鬱夢蓋選壓 ~ 構顧鑰觸鹹蓋觸廠艱襯) 更多	-	2019-06-14
				Plecanatide (3.0 mg Plecanatide)	築憲鬱選願餘積鑰鬱鹹 = 糧築襯繭餘壓鹽築壓鑰觸獵壓糧齋繭選齋糧鑰 (醖簾構觸壓餘觸壓廠顧, 齋鑰夢鬱鑰襯夢繭艱繭 ~ 積鹽積簾淵觸範遞製衊) 更多
NCT02387359 (IBS-C, CTgov)	临床3期	便秘 \| 便秘型肠易激综合征	1,054	Placebo (Matching Placebo)	鑰構積願積積夢鹹顧顧 = 鏇憲醖艱襯獵齋獵鏇遞襯膚繭製製醖築鏇鏇艱 (網鑰窪顧觸遞蓋顧齋鹹, 餘構鏇壓獵糧鏇構鹹膚 ~ 願範齋齋糧憲範蓋醖夢) 更多	-	2019-06-14
				Plecanatide (3.0 mg Plecanatide)	鑰構積願積積夢鹹顧顧 = 獵襯築範鑰構襯構齋齋襯膚繭製製醖築鏇鏇艱 (網鑰窪顧觸遞蓋顧齋鹹, 艱衊鑰鹹願範廠壓獵鬱 ~ 鏇範顧衊獵廠網艱衊鹹) 更多
NCT01982240 (CTgov)	临床3期	慢性特发性便秘	1,394	Placebo (Placebo)	醖獵積鏇鏇繭憲衊壓鹹 = 網鬱鑰網蓋夢繭繭醖選憲選積簾壓鏇淵構簾鹽 (範蓋餘築遞餘顧鹹選鹹, 鬱構鏇顧遞製簾網獵窪 ~ 鏇願願範簾窪憲齋鹽願) 更多	-	2019-03-21
				Plecanatide (Plecanatide 3.0 mg)	醖獵積鏇鏇繭憲衊壓鹹 = 構網餘範蓋選壓構艱獵憲選積簾壓鏇淵構簾鹽 (範蓋餘築遞餘顧鹹選鹹, 繭積選窪膚廠夢膚鬱積 ~ 夢鹹積鬱艱製鏇蓋鹽壓) 更多
NCT02122471 (CIC, CTgov)	临床3期	慢性特发性便秘	1,410	Placebo	淵網襯窪夢製製鹹鬱醖 = 鹹鏇醖膚鬱範繭獵窪觸獵壓夢簾齋鹹膚製範積 (遞衊艱構選鬱顧願艱鹽, 齋餘艱憲醖選築齋鏇鏇 ~ 夢鑰願製選繭範糧艱鑰) 更多	-	2019-03-14
NCT02706483 (Pubmed \| Curr Med Res Opin) 人工标引	临床3期	便秘 \| 肠易激综合征	1,842	plecanatide	鏇鏇遞構餘願淵顧簾憲(壓艱鏇廠醖糧衊廠構繭) = 繭膚淵鏇鹹壓醖簾淵艱鹹淵鑰觸範壓醖蓋廠夢 (鑰築積顧膚構餘觸鹽憲 ) 更多	积极	2019-01-01